247 related articles for article (PubMed ID: 35931676)
1. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells.
Tan Y; Li J; Zhao G; Huang KC; Cardenas H; Wang Y; Matei D; Cheng JX
Nat Commun; 2022 Aug; 13(1):4554. PubMed ID: 35931676
[TBL] [Abstract][Full Text] [Related]
2. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
3. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
Sullivan EJ; Kurtoglu M; Brenneman R; Liu H; Lampidis TJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):417-27. PubMed ID: 24352250
[TBL] [Abstract][Full Text] [Related]
4. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
Papaevangelou E; Almeida GS; Box C; deSouza NM; Chung YL
Int J Cancer; 2018 Aug; 143(4):992-1002. PubMed ID: 29569717
[TBL] [Abstract][Full Text] [Related]
5. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
6. Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment.
Hernlund E; Hjerpe E; Avall-Lundqvist E; Shoshan M
Mol Cancer Ther; 2009 Jul; 8(7):1916-23. PubMed ID: 19567816
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
[TBL] [Abstract][Full Text] [Related]
8. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
9. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
10. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.
Matassa DS; Amoroso MR; Lu H; Avolio R; Arzeni D; Procaccini C; Faicchia D; Maddalena F; Simeon V; Agliarulo I; Zanini E; Mazzoccoli C; Recchi C; Stronach E; Marone G; Gabra H; Matarese G; Landriscina M; Esposito F
Cell Death Differ; 2016 Sep; 23(9):1542-54. PubMed ID: 27206315
[TBL] [Abstract][Full Text] [Related]
11. Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer.
Wangpaichitr M; Wu C; Li YY; Nguyen DJM; Kandemir H; Shah S; Chen S; Feun LG; Prince JS; Kuo MT; Savaraj N
Oncotarget; 2017 Jul; 8(30):49275-49292. PubMed ID: 28525376
[TBL] [Abstract][Full Text] [Related]
12. A platinum(II) complex HY1-Pt overcomes cisplatin-induced resistance and attenuates metastasis of epithelial ovarian cancer by cancer cell stemness inhibition.
Wang X; Wang Y; Gou S
Int J Biochem Cell Biol; 2023 Apr; 157():106395. PubMed ID: 36871936
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.
Ishibashi M; Toyoshima M; Zhang X; Hasegawa-Minato J; Shigeta S; Usui T; Kemp CJ; Grandori C; Kitatani K; Yaegashi N
Sci Rep; 2018 Sep; 8(1):13207. PubMed ID: 30181600
[TBL] [Abstract][Full Text] [Related]
15. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
16. Altered glutamine metabolism in platinum resistant ovarian cancer.
Hudson CD; Savadelis A; Nagaraj AB; Joseph P; Avril S; DiFeo A; Avril N
Oncotarget; 2016 Jul; 7(27):41637-41649. PubMed ID: 27191653
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
18. Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.
Matsumura S; Ohta T; Yamanouchi K; Liu Z; Sudo T; Kojimahara T; Seino M; Narumi M; Tsutsumi S; Takahashi T; Takahashi K; Kurachi H; Nagase S
Cancer Biol Ther; 2017 Sep; 18(9):730-739. PubMed ID: 27689466
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
20. LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3p.
Hua G; Zeng ZL; Shi YT; Chen W; He LF; Zhao GF
Pharmacology; 2021; 106(9-10):498-508. PubMed ID: 34352791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
